Avid Bioservices Inc (CDMO)

[north40000]

WH, while you’re looking for good, but risky, investments, take a long look at AMRN and the clinical trial P. I. Dr. C. Carlsson at U. Wisconsin recently released, anticipating (IMO) a potential accelerated FDA approval of Vascepa in Alzheimer’s Disease, dementia, PTSD, depression, etc. The Phase 3 BRAVE trial of Vascepa completed 9/29/2023, after running for greater than 2-6 years, and her hypothesis + AIMS 1-3 are now under data analysis. I have been prescribed Vascepa (4 capsules/day) since 4/2013. The plan for BRAVE trial now is to run a Phase 4 confirmatory trial of 18 months in more patients to show FDA that the data ensuing from AIMS 1-3 do reveal Vascepa effectiveness in treating biomarkers. My mother died in 2000, not Knowing my brother or me.